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ABSTRACT
Background Protein S100B has proven to be a useful
biomarker for cerebral damage. The predictive ability of
S100B may, however, be affected by extracerebral
injuries. The aim of this study was to investigate serum
levels of S100B in patients with either isolated head
injury (IHI), multi trauma with head injury (MTHI), or no
head injury (NHI). The primary aim was to assess if
a signiﬁcant difference in serum levels of S100B could be
found between IHI and MTHI patients.
Methods Patients (233) were primarily admitted to the
trauma centre. Serum samples were drawn on
admission and 6 h after trauma and then stored at
 808C until analysed. Variables included Abbreviated
Injury Scale (AIS) for head trauma, Injury Severity Score
(ISS) and 30-day survival.
Results Two patients could not be classiﬁed. IHI
occurred in 28, MTHI in 102 and NHI was found in 101.
The median S100B concentrations on arrival were 0.47,
1.68 and 0.49 mg/l, respectively (p<0.0001). The
corresponding values at 6 h were 0.14, 0.31 and
0.15 mg/l, respectively (p<0.0001). S100B was
signiﬁcantly higher in patients with MTHI than in patients
with IHI at both time points (p values 0.0005 and 0.01).
There was no signiﬁcant difference in S100B between
patients having IHI and patients with NHI (p¼0.81 and
p¼0.67).
Conclusions High serum levels of S100B were found
early after trauma. The highest concentrations of S100B
were found in patients with multi trauma. This suggests
that S100B serum concentrations are signiﬁcantly
affected by extracerebral injuries.
INTRODUCTION
The S100 proteins are members of the calmodulin/
troponin C superfamily of calcium binding
proteins.
1 2 This protein family includes approxi-
mately 25 members, of which one, S100B, is
predominantly expressed in nervous tissue, but
also, to a lesser extent, in other tissues such as fat,
muscle,
3 melanocytes and long bones. Conse-
quently, S100B can be released in the cases of
cerebral and extracerebral injury.
4 S100B has intra-
cellular and extracellular physiological functions. It
is secreted by astrocytes in the brain where it has
several intracellular functions, including being part
of the cytoskeleton and a modulator of the cell
cycle. The extracellular functions are reparative and
toxic,
5 and extracellular S100B has been shown to
inhibit myoblast differentiation in rats.
6
As S100B is predominantly expressed by nervous
tissue it has been suggested as a marker for trau-
matic and anoxic brain damage. A reliable biomarker
of cerebral injury is of clinical relevance in minor and
major head trauma, as it could reduce the number of
negative CT scans. Undén et al
7 found that S100B
could theoretically reduce CTscans after minor head
injury by more than 30%, with maintained patient
safety. Furthermore, studies have shown serum
levels of S100B to be directly proportional to the
severity of injury.
4 Also, Vos et al
8 found that
patients with poor outcomes (Glasgow Outcome
Scale (GOS) 1e3) had signiﬁcantly higher serum
S100B levels than patients with better outcomes
(GOS 4e5) (p<0.01). Therefore, S100B measure-
ments could provide clinicians with valuable infor-
mation regarding prognosis and relevant therapeutic
actions. Previous studies have demonstrated that the
serum levels of S100B can predict pathological
ﬁndings on CTafter minor head injury with a high
sensitivity (99%)
9 for brain organ damage as well as
epidural bleeding. There are indications that the use
of S100B could prove to be very cost-effective, safe
and perhaps even more sensitive than cerebral CTas
it is free from subjective analytical error.
9 The
problem, however, using S100B as a screening tool, is
the positive predictive value, which has been shown
to be no more than around 30%.
9
A general topic of debate, regarding the use of
biomarkers in trauma patients, has been the role of
the half life of the biomarker in question. Therefore,
it has been suggested that blood samples should be
collected at speciﬁc time points after the injury.
Regarding S100B, additional knowledge on serum
levels in different types of trauma and at different
time points would be of interest, as studies have
shown that the predictive ability is affected by
extra cerebral injuries, such as fractures of the long
bones,
10 thoracic contusions, burns and minor
bruises.
11 These ﬁndings have resulted in sugges-
tions of combining measurements of S100B with
other biomarkers, including a careful assessment of
peripheral non-cerebral injuries.
3 The purpose
of the present study was to investigate serum levels
of S100B on admission and 6 h post injury, in order
to assess the possible difference between patients
with isolated head injury (IHI), non-head injury
(NHI) and multiple trauma with head injury
(MTHI). The primary hypothesis was that there is
a signiﬁcant difference in serum levels of S100B on
admission between patients with head injury only
and patients with multiple injuries, deﬁned as head
injury in combination with other injuries.
MATERIALS AND METHODS
This study was registered at http://www.ClinicalTrials.
gov (Identiﬁer: NCT00192907).
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Original articlePatients
Trauma patients primarily admitted to the level one trauma
centre at Rigshospitalet, Copenhagen from 2004 to 2005 were
included in the study. Patients were enrolled if the trauma team
was activated and major trauma was suspected, deﬁned as need
for blood sampling. The following exclusion criteria were
applied:
< Age < 18 years
< Diabetes mellitus, immunodeﬁciency
< Pregnancy
< Major burns (total body surface area of a burn >10%)
< Steroid treatment within 24 h
Patient characteristics have previously been described by
Stensballe et al.
12 This study described serum levels of inter-
leukin (IL) 6 and IL 10 in response to trauma and was the basis
for the applied exclusion criteria.
Clinical and radiological examination
Neurological examination and assessment of level of
consciousness, according to the Glasgow Coma Score (GCS),
were performed on all patients on arrival. In cases where
patients were tracheally intubated on arrival, or unable to
cooperate to the neurological evaluation, they were registered as
having a GCS of 3.
In all patients the extent of trauma was classiﬁed according to
the Injury Severity Score (ISS). ISS is based on the Abbreviated
Injury Scale (AIS), describing each lesion in six distinct
anatomical body regions. The AIS score of the three most
severely injured body regions was squared and added together to
produce the ISS score. Where the AIS score was unavailable the
ISS score was estimated from the patient’s medical record.
CT of the brain was performed according to an institutional
standardised protocol using 5 mm slices, accessing signs of
traumatic cranial and intracranial injuries such as haemorrhage,
oedema and fracture. This information was used to assess the
degree of head injury using the AIS protocol.
S100B analysis
Blood samples were drawn on admission and 6 h after the
trauma. Blood samples were obtained without or with minimal
haemostasis (<30 s), ice-cooled, and, immediately after clotting,
centrifuged at 2000 g for 10 min. Serum samples were frozen
within 1 h of sampling, and stored at  808C until analysed. The
analysis was performed using a fully automated electro-
chemiluminescence immunoassay (Roche Diagnostics)
performed on a Modular E with an analytical sensitivity of
0.005 mg/l, and a functional sensitivity of 0.02 mg/l. The
analytical range of this test is 0.005e39 mg/l. The interassay
variation was less than 3%.
Statistical analysis
ManneWhitney U and Kruskall-Wallis tests were used to
compare serum levels of S100B on admission and at 6 h
according to type of injury. Variables include age, gender, 30-day
survival, AIS for head trauma score (AIS
head), GCS and ISS.
e No head injury was deﬁned as an AIS
head ¼ 0
e Multi trauma with head injury was deﬁned as ISS > (AIS
head)
2
e Isolated head injury was deﬁned as (AIS
head)
2 ¼ ISS.
p Values<0.05 were statistically signiﬁcant.
RESULTS
Inclusion
A total of 901 patients arrived as trauma alerts, but only 402
were at least 18 years of age and needed blood sampling on
arrival. Data collection was incomplete in 65, 61 were discharged
within 6 h due to minimal injury, 41 fulﬁlled exclusion criteria
and two withdrew consent.
Accordingly, 233 patients were included in the study where
208 blunt traumas and 25 penetrating traumas were recorded.
Two-hundred and three blood samples were obtained on arrival
and 198 at 6 h. The average time from trauma to the ﬁrst serum
sample was 40 min (table 1). Blood samples from both time
points were available in 168 patients, and S100B levels were
signiﬁcantly lower at 6 h compared to arrival.
S100B serum levels were signiﬁcantly different between the
three groups on arrival and at 6 h (p<0.0001). S100B was signif-
icantly higher in patients with MTHI than in patients with IHI
at both time points (p¼0.0005 and p¼0.01 respectively). There
was no signiﬁcant difference in S100B levels between patients
having IHI and NHI (p¼0.8 and p¼0.7) (table 1).
Likewise, there was no signiﬁcant difference in AIS head
trauma scores between MTHI patients and IHI patients
(p¼0.98).
In the IHI and MTHI groups S100B levels were found to be
above 0.1 mg/l in 92% and 98% of the patients respectively (table 2).
Seventy-four per cent of the patients in the NHI group had
values above 0.1 mg/l.
Epidural haemorrhage was seen in four patients. S100B levels
were above 0.9 mg/l on arrival in all four patients (table 3).
DISCUSSION
This study shows that extracerebral injuries have a signiﬁcant
impact on the predictive ability of S100B regarding traumatic
brain damage. Higher values of S100B were found in the multi
traumatised patients than in the IHI group. It was hypothesised
that this difference in S100B between the MTHI and the IHI
groups could be caused by higher values of the AIS head injury
parameter in the MTHI. However, no such difference was
Table 1 Trauma patient characteristics and S-100B serum values
Isolated head
injury (N[28)
Multi trauma with head
injury (N[102)
No head injury
(N[101) p Value
Age, years 40.7 (27.0e54.5) 42.0 (26.3e57.0) 33.9 (25.0e46.0) 0.06
Gender, male 20 (71.4%) 77 (75.5%) 76 (75.3%) 0.90
ISS 6.5 (4.0e9.0) 16.5 (8.0e29.0) 9.0 (4.0e12.0) N/A
AIS, Head trauma 2.7 (2.0e3.0) 2.8 (2.0e4.0) N/A N/A
S100B on arrival, mg/l 0.47 (0.24e1.11) 1.68 (0.71e6.10) 0.49 (0.10e2.16) <0.0001
S100B at 6 h mg/l 0.14 (0.09e0.29) 0.31 (0.16e0.51) 0.15 (0.06e0.30) <0.0001
Mortality at 30 days 1 (3.6%) 18 (17.7%) 3 (3.0%) 0.0009
GCS 14 (9.5e15) 13 (6e15) 15 (15e15) 0.8
Continuous variables reported as median with (IQR), other data reported with proportions.
AIS, Abbreviated Injury Scale; ISS, Injury Severity Score; GCS, Glasgow Coma Score; p, Kruskall Wallis test or c
2 test.
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found that in the group of patients with no history or sign of
head injury, 74% had values above this limit and there was no
signiﬁcant difference in the S100B serum levels on arrival or at
6 h between the IHI and NHI groups.
The present ﬁndings are relevant in the process of determining
the indications for S100B screening. Other studies have inves-
tigated patients with isolated minor head injury and found that
a GCS of 14e15 is an ideal indication for using S100B as a tool
for CT triage.
7 91 3It seems that substantial extracerebral
damage severely compromises the use of S100B as a screening
tool. This is supported by other studies done on patients with no
head injury showing elevated serum levels of S100B.
89
There is some controversy regarding the optimal time for
serum sampling to achieve the greatest predictive value of
S100B. Some studies have shown that circulating levels of S100B
reach peak values 20 min after injury,
14 and it would seem that
the maximal sensitivity could be achieved by early sampling.
However, as the present study has shown, the extracerebral
contribution is a signiﬁcant factor and other authors suggest
that S100B determination earlier than 6 h after injury may
increase false-positive results.
14 Furthermore, Raabe et al
14
showed S100B concentration to be highly time-dependent in the
ﬁrst 3e4 h, whereas at 6 h levels are stable and the exact
sampling time would be less important. It has been demon-
strated that extracerebral S100B has a shorter half life than
intracerebral S100B, thus it is suspected that sampling again
after 6 h could help differentiate between groups of injury. A
signiﬁcant decrease in serum levels was found after 6 h, but still
no difference could be found between patients with IHI and
NHI. This indicates that sampling after 6 h would not improve
the predictive value of S100B.
Da Rocha et al
15 found S100B to be a predictive parameter for
fatal outcome in patients with IHI and in multi traumatised
patients. They found no differences in serum S100B levels of
multi trauma victims with severe traumatic brain injury (TBI)
compared to those with isolated severe TBI, indicating that the
extracerebral contribution was insigniﬁcant at least for the
prognostic value of S100B. In contrast, others have demonstrated
as i g n i ﬁcant extracerebral release and concluded that S100B is not
suitable as a predictor for intracerebral injury in patients with
substantial extra cerebral injuries.
9 The present ﬁndings support
this view in demonstrating no signiﬁcant difference in the
predictive value of S100B between IHI and NHI patients.
A future prospect in the use of S100B as a tool for screening
could be the development of a protocol for pattern recognition
using other biomarkers. One possibility could be the use of glial
ﬁbrillar acidic protein (GFAP), which has been shown to be
a very speciﬁc biomarker for central nervous system pathological
abnormality.
16e18 Perhaps a combined measurement of S100B
and a GFAP test could provide a higher speciﬁcity for intracranial
pathology than serum S100B values alone. More research on the
clinical applicability of serum-GFAP is needed. Other biomarkers
should also be considered, among those markers for extracerebral
injury such as Gc-globulin, which has proven to be highly and
almost immediately sensitive to muscle damage.
19 20 Measuring
Gc-globulin levels could serve as an indicator of the amount of
extracerebral injury and thereby help the interpretation of S100B
serum values.
The ISS scoring system is an index based on the severity of the
anatomical injury sustained and this allowed for a reasonable
classiﬁcation. However, the ISS does not take into account the
mechanism of trauma (blunt/penetrating), physiological
confounders or concurrent medical disease, all of which could
have an impact on the S100B serum levels. Increased S100B has
been associated with cerebral infectious diseases, heart ischaemia
and neurodegenerative disease.
21e23 Another limitation of this
study is that different physicians performed the ISS scoring
throughout the study. This kind of scoring is to some extent
subjective and some interobserver variability is inevitable. All
patients in the present study were primarily admitted from the
scene of the accident and the number of subjects with severe
head injury was limited. A high proportion of secondarily
admitted patients with severe head injury is usually seen in
tertiary trauma centres, and, therefore, the value of S100B may
be different in that setting. A beneﬁt of S100B may not be
detectable due to a type 2 error, if the number of patients with
intracranial pathology is low. This could also be relevant to the
inability to detect a difference in S100B levels between patients
having IHI and NHI. In total, these groups constituted a sample
of nearly 130 patients, which allowed detection of a stand-
ardised difference of 0.5 with 80% power at the 5% signiﬁcance
level. Unfortunately, the variation in S100B was very large,
especially at arrival, where the calculated standardised difference
was around 4 mg/l in patients with NHI.
In conclusion, elevated serum concentrations of S100B were
found early after trauma, especially in patients with multi
trauma. This suggests that S100B serum concentrations are
signiﬁcantly affected by extracerebral injuries.
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Table 2 S100B serum concentrations according to intracranial
pathology detected by cerebral CT (CCT) in trauma patients
S100B arrival CCT pathology No CCT pathology Total
Multi trauma >0.1 mg/l 41 (98%) 44 (94%) 85
<0.1 mg/l 1 (2%)* 3 (6%) 4
42 47 89
Isolated head injury >0.1 mg/l 11 (92%) 14 (87%) 25
<0.1 mg/l 1 (8%)y 2 (13%) 3
12 16 28
No head injury >0.1 mg/l N/A 61 (74%) 61
<0.1 mg/l N/A 21 (26%) 21
N/A 82 82
*Diffuse axonal injury.
yMild cerebral oedema.
Table 3 Median S100B values in four patients with epidural
haemorrhage
1234
Arrival S100B mg/l 3.57 0.966 6.31 1.01
6 h S100B mg/l 0.644 0.264 0.403 0.452
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